• Skip to Content

.

 Indiana University Indiana University IU

Search

IU Simon Comprehensive Cancer Center Indiana University Melvin and Bren Simon Comprehensive Cancer CenterA National Cancer Institute Comprehensive Cancer Center

  • About Us
    • Our Mission & Goals
    • Our Leadership
    • Our Members (Scientists, Physician-scientists)
    • Our Partners
    • Travel
  • Research & Clinical Trials
    • Clinical Trials
    • Research Programs
    • DHART SPORE
    • Member Directory
    • Become a Member
    • Shared Facilities
    • Research Resources
    • Funding Opportunities
    • Refer a Patient
  • Career Enhancement & Related Activities
    • Aims
    • Training Programs
    • Trainee Membership
    • Fellowships
    • Presentations
    • Cancer Research Day
    • Amelia Project
    • Andrea Gianaris Pancreatic Cancer Symposium
    • William J. Wright Scholarship Fund
  • News & Publications
    • News
    • News Archives
    • Publications
  • Office of Community Outreach & Engagement
  • Giving
Staff Login
  • Patient Care at IU Health
  • IU School of Medicine
  • Research & Clinical Trials
  • Clinical Trials
  • Find a Trial
  • Trial Results

Research & Clinical Trials

Find a Trial

Trial Results


5 protocol(s) meet the specified criteria
ARO-021OPEN TO ACCRUAL
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
CTO-AT148002OPEN TO ACCRUAL
A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS)
CTO-CLR-15-03OPEN TO ACCRUAL
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
CTO-INCB-50465-304OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib.
CTO-KO-MEN-001OPEN TO ACCRUAL
A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
  • Clinical Trials
    • About Clinical Trials
    • Should I Participate?
    • Find a Trial
      • by Cancer Type
      • by Doctor
      • by Institution
    • Biobanking: Donating a Part of You to Help Find a Cure.
    • Scientific Review Committee Resources
  • Research Programs
  • DHART SPORE
  • Member Directory
  • Become a Member
  • Shared Facilities
  • Research Resources
  • Funding Opportunities
  • Refer a Patient
NCI-CC A Cancer Center Designated by the National Cancer Institute Big 10 Cancer Research Consortium
Give Now
Fundraising Disclosures: http://go.iu.edu/89n

Block IU Copyright ©  The Trustees of Indiana University, Copyright Complaints, Privacy Notice

Indiana University Melvin and Bren Simon Comprehensive Cancer Center | 535 Barnhill Drive | Indianapolis, IN 46202
Patient Care: (888) 600-4822 | Administrative Office: (317) 278-0070

For accessibility or website issues, contact the webmaster.